Avonex Safety and Tolerability in Chinese Subjects With Relapsing Mult

An Open-Label Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Avonex (Interferon Beta-1a) in Chinese Subjects With Relapsing Multiple Sclerosis

CompletedPhase 3Relapsing MSNCT01181115

What it found

No results found

We found no results in the registry or in papers.

This trial finished 15 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

What it measured

Main measures

  • The number and proportion of subjects with adverse events (AEs)

    24 weeks

    Safety

  • Assessment of clinical laboratory parameters

    24 weeks

  • Assessment of vital signs and physical examinations

    24 weeks

    Safety

  • Assessment of electrocardiogram (ECG)

    24 weeks

  • Assessment of immunogenicity

    24 weeks

    Immune response

  • Incidence of depression

    24 weeks

    Mood and sleep

  • Incidence of flu-like symptoms

    24 weeks

    Safety

  • Subject assessment of injection site pain

    24 weeks

    PainSafety

  • Clinical assessment of the injection site

    24 weeks

    Safety

Other measures (5)

  • Assess safety of Avonex by evaluating changes in the Expanded Disability Status Scale (EDSS) score over time

    24 weeks

    Disability progressionSafety

  • Number of Gd-enhancing lesions on brain MRI scans taken after 3 and 6 months following Avonex treatment

    at month 3 and month 6

    MRI lesions

  • Number of new or newly enlarging T2-weighted lesions on brain MRI scans taken after 3 and 6 months following Avonex treatment

    at month 3 and month 6

    MRI lesions

  • Volume of T2-weighted lesions on brain MRI scans taken after 6 months following initiation of Avonex treatment

    month 6

    MRI lesions

  • Assess pharmacodynamic response to Avonex by evaluating the change from baseline in serum levels of neopterin

    24 weeks

Who could take part

Relapsing MS · 18 to 55 · EDSS 0 to 5

Show the full criteria

Inclusion criteria

* Ability to understand risks of study and provide informed consent. * Must be Chinese, aged 18 to 55 years inclusive at time of consent. * Must have diagnosis of relapsing MS of 3 months duration at time of screening visit. * Must have at least 1 documented MS attack within 3 years of Day 1. * Must have EDSS score of 0 to 5 inclusive at screening visit. * All male subjects \& female subjects of child-bearing potential must practice effective contraception during the study.

Exclusion criteria

* Have a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS. * Have had a clinical MS attack within the 50 days prior to Day 1, and or the subject has not stabilized from a previous attack in the opinion of the Investigator. * The subject is unable to undergo a brain MRI scan for any reason. * The subject's screening and Day 1 MRIs are both normal (negative) for lesions consistent with MS (Gd-enhancing lesions are not required, but one of the 2 MRIs should be consistent with MS). * History of severe allergic or anaphylactic reactions. * Known allergy to any component of the Avonex Formulation. * History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal or other major disease. * Subjects with a history of malignant disease, including solid tumors, and hematologic malignancies (except basal cell and squamous cell carcinomas of the skin that have been completely excised and considered cured). * History of seizure disorder or unexplained blackouts OR history of a seizure within 6 months prior to Day 1. * History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator) within 6 months prior to Day 1. Note: subjects receiving ongoing antidepressant therapy will not be excluded from the study unless the medication has been increased within the 6 months prior to Day 1. * Clinically significant abnormal ECG values as determined by the Investigator. * Known history of human immunodeficiency virus (HIV). * Known history of, or positive test result for hepatitis C virus (test for hepatitis C virus antibody HCV Ab) or hepatitis B virus (test for Hepatitis B surface Antigen HBsAg) and/or Hepatitis B Core Antibody (HBcAb).

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

The study is designed to determine the effect of weekly intramuscular (IM) administration of 30 mcg Avonex (interferon beta 1a) on safety parameters and gadolinium (Gd) enhanced and T2-weighted cranial magnetic resonance imaging (MRI) lesions in Chinese patients with clinically diagnosed (using revised McDonald criteria) relapsing multiple sclerosis (MS).

Loading reviews and guidelines…

Related trials

History

    1. Started

      Apr 2010

    2. Main results due

      Oct 2011

    3. Finished

      Oct 2011

    Assembled by software from public sources.